The new independent kidney-care company will be equally co-owned by both companies. It will include all of Medtronic’s renal care solutions business, including renal access, acute therapies, and chronic therapies.

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

The kappa opioid receptor agonist is not listed as a scheduled substance and labeling meets expectations. Cara and partner Vifor plan to launch the product in early 2022.

The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.